Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

In vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.

Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2019 Apr 29. pii: AAC.00624-19. doi: 10.1128/AAC.00624-19. [Epub ahead of print]

PMID:
31036691
2.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis.

Zhao M, Lepak AJ, Marchillo K, Vanhecker J, Sanchez H, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02372-18. doi: 10.1128/AAC.02372-18. Print 2019 Apr.

PMID:
30670426
3.

In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01067-18. doi: 10.1128/AAC.01067-18. Print 2018 Sep.

4.

Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.

Park JH, Craig W, Marchillo K, Huang DB, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02550-17. doi: 10.1128/AAC.02550-17. Print 2018 Apr.

5.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

6.

In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00250-17. doi: 10.1128/AAC.00250-17. Print 2017 Jul.

7.

In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02368-16. doi: 10.1128/AAC.02368-16. Print 2017 May.

8.

Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms.

Nett JE, Cabezas-Olcoz J, Marchillo K, Mosher DF, Andes DR.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3152-5. doi: 10.1128/AAC.03094-15. Print 2016 May.

9.

Intraluminal Release of an Antifungal β-Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection.

Raman N, Marchillo K, Lee MR, Rodríguez López AL, Andes DR, Palecek SP, Lynn DM.

ACS Biomater Sci Eng. 2016 Jan 11;2(1):112-121. Epub 2015 Dec 8.

10.

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.

Lepak A, Marchillo K, VanHecker J, Azie N, Andes D.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):674-7. doi: 10.1128/AAC.02124-15. Print 2016 Jan.

11.

Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.

Lepak A, Marchillo K, VanHecker J, Andes D.

Antimicrob Agents Chemother. 2015 Dec;59(12):7833-6. doi: 10.1128/AAC.01717-15. Epub 2015 Sep 21.

12.

Host contributions to construction of three device-associated Candida albicans biofilms.

Nett JE, Zarnowski R, Cabezas-Olcoz J, Brooks EG, Bernhardt J, Marchillo K, Mosher DF, Andes DR.

Infect Immun. 2015 Dec;83(12):4630-8. doi: 10.1128/IAI.00931-15. Epub 2015 Sep 14.

13.

In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.

Lepak AJ, Parhi A, Madison M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2015 Oct;59(10):6568-74. doi: 10.1128/AAC.01464-15. Epub 2015 Aug 10.

14.

Nontoxic antimicrobials that evade drug resistance.

Davis SA, Vincent BM, Endo MM, Whitesell L, Marchillo K, Andes DR, Lindquist S, Burke MD.

Nat Chem Biol. 2015 Jul;11(7):481-7. doi: 10.1038/nchembio.1821. Epub 2015 Jun 1.

15.

Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Lepak AJ, Marchillo K, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. doi: 10.1128/AAC.04445-14. Epub 2014 Dec 15.

16.

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

Lepak AJ, Marchillo K, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1258-64. doi: 10.1128/AAC.04444-14. Epub 2014 Dec 15.

17.

Rat indwelling urinary catheter model of Candida albicans biofilm infection.

Nett JE, Brooks EG, Cabezas-Olcoz J, Sanchez H, Zarnowski R, Marchillo K, Andes DR.

Infect Immun. 2014 Dec;82(12):4931-40. doi: 10.1128/IAI.02284-14. Epub 2014 Sep 2.

18.

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D.

Antimicrob Agents Chemother. 2014 Oct;58(10):6311-4. doi: 10.1128/AAC.03572-14. Epub 2014 Aug 4.

19.

Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6284-9. doi: 10.1128/AAC.01355-13. Epub 2013 Oct 7.

20.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.

21.

Synthesis and antibacterial activity of doxycycline neoglycosides.

Zhang J, Ponomareva LV, Marchillo K, Zhou M, Andes DR, Thorson JS.

J Nat Prod. 2013 Sep 27;76(9):1627-36. doi: 10.1021/np4003096. Epub 2013 Aug 29.

22.

Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47. doi: 10.1128/AAC.00833-13. Epub 2013 Aug 19.

23.

Preparation of Candida albicans Biofilms Using an in vivo Rat Central Venous Catheter Model.

Taff HT, Marchillo K, Andes DR.

Bio Protoc. 2013 Jul 20;3(14). pii: e823.

24.

Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Jan;57(1):579-85. doi: 10.1128/AAC.01279-12. Epub 2012 Nov 12.

25.

Natural product disaccharide engineering through tandem glycosyltransferase catalysis reversibility and neoglycosylation.

Peltier-Pain P, Marchillo K, Zhou M, Andes DR, Thorson JS.

Org Lett. 2012 Oct 5;14(19):5086-9. doi: 10.1021/ol3023374. Epub 2012 Sep 17.

26.

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.

27.

Modeling of fungal biofilms using a rat central vein catheter.

Nett JE, Marchillo K, Andes DR.

Methods Mol Biol. 2012;845:547-56. doi: 10.1007/978-1-61779-539-8_40.

28.

Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, Ghannoum MA, Knapp C, Lockhart SR, Ostrosky-Zeichner L, Walsh TJ, Marchillo K, Messer S, Welshenbaugh AR, Bastulli C, Iqbal N, Paetznick VL, Rodriguez J, Sein T.

Antimicrob Agents Chemother. 2011 Apr;55(4):1543-8. doi: 10.1128/AAC.01510-09. Epub 2011 Jan 31.

29.

Development and validation of an in vivo Candida albicans biofilm denture model.

Nett JE, Marchillo K, Spiegel CA, Andes DR.

Infect Immun. 2010 Sep;78(9):3650-9. doi: 10.1128/IAI.00480-10. Epub 2010 Jul 6.

30.

Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene.

Nett JE, Crawford K, Marchillo K, Andes DR.

Antimicrob Agents Chemother. 2010 Aug;54(8):3505-8. doi: 10.1128/AAC.00227-10. Epub 2010 Jun 1.

31.

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506. doi: 10.1128/AAC.01584-09. Epub 2010 Apr 12.

32.

Engineering of Streptomyces platensis MA7339 for overproduction of platencin and congeners.

Yu Z, Smanski MJ, Peterson RM, Marchillo K, Andes D, Rajski SR, Shen B.

Org Lett. 2010 Apr 16;12(8):1744-7. doi: 10.1021/ol100342m.

33.

Time course global gene expression analysis of an in vivo Candida biofilm.

Nett JE, Lepak AJ, Marchillo K, Andes DR.

J Infect Dis. 2009 Jul 15;200(2):307-13. doi: 10.1086/599838.

34.

In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J.

Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.

35.

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J.

Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. Epub 2007 Dec 10.

36.

Beta -1,3 glucan as a test for central venous catheter biofilm infection.

Nett J, Lincoln L, Marchillo K, Andes D.

J Infect Dis. 2007 Jun 1;195(11):1705-12. Epub 2007 Apr 17.

PMID:
17471441
37.

Eap1p, an adhesin that mediates Candida albicans biofilm formation in vitro and in vivo.

Li F, Svarovsky MJ, Karlsson AJ, Wagner JP, Marchillo K, Oshel P, Andes D, Palecek SP.

Eukaryot Cell. 2007 Jun;6(6):931-9. Epub 2007 Apr 6.

38.

Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.

Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, VanHandel M, Andes D.

Antimicrob Agents Chemother. 2007 Feb;51(2):510-20. Epub 2006 Nov 27.

39.
40.

Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L.

Antimicrob Agents Chemother. 2006 Jul;50(7):2374-83.

41.
43.

A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site.

Andes D, Lepak A, Pitula A, Marchillo K, Clark J.

J Infect Dis. 2005 Sep 1;192(5):893-900. Epub 2005 Jul 25.

PMID:
16088840
44.

Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A.

Infect Immun. 2004 Oct;72(10):6023-31.

45.

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jan;48(1):137-42.

46.

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Andes D, Marchillo K, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Oct;47(10):3165-9.

47.

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

Andes D, Marchillo K, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Apr;47(4):1193-9.

48.

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Apr;47(4):1187-92.

Supplemental Content

Loading ...
Support Center